DeNovX's first company-owned patent issued on November 24, 2015 in a comparatively rare "first action allowance" (i.e., no objections from USPTO). The allowance took just under 18 months, well ahead of the 29 month average pendency for this group of examiners. The patent covers new and more efficient methods of creating crystalline materials for use in the food, pharmaceutical, medical nutrition, nutraceutical, cosmetic, agricultural, fine chemicals, and bioengineering fields, with initial target customers in pharmaceutical R&D and specialty Contract Research Organizations (CROs) where the crystallization of small molecule Active Pharmaceutical Ingredients (APIs) is a challenging and important early step in drug development. Contact Us if [...]

DeNovX has moved in to its newest lab facility in the Technology Park on the campus of Illinois Institute of Technology.  Completely renovated and opened in 2011, the laboratory facility is state of the art and will allow DeNovX to efficiently and safely commercialize its pharmaceutical discovery and manufacturing technologies-with room to grow when needed. University Technology Park in Chicago DeNovX lab facilities for crystallization development   Technology Business Center

DeNovx was awarded a $224,000 Phase I Small Business Innovative Research grant from the National Institutes of Health to develop new approaches to improve protein crystallization success rates in support of structural biology. The role of structural biology in facilitating an understanding of biological function is well established, and advances in crystallization methods will assist researchers in overcoming crystallization as a major source of attrition in their investigative pipelines. Improvements in protein crystallization outcomes will positively impact productivity in structural biology, with public health benefits accruing from faster knowledge acquisition and more efficient drug development. The long term objective of this work [...]

DeNovX was featured in the summer newsletter for the ACS Division of Small Chemical Business in an article on the National Entrepreneur Showcase East, where DeNovX won the Best Pitch Award.  Read more on page 11 here.

After receiving multiple grants and awards from iBIO's PROPEL program, DeNovX and their win at a national Best Pitch competition (see 4/10/2014 posting) were featured in the Summer edition of BioLogical Quarterly.  In reference to his experiences with the PROPEL mechanism and their staff, Dr. Andrew Bond commented that "PROPEL’s depth and quality of services, educational functions and networking opportunities make it a valuable resource for entrepreneurs that cannot be overlooked or understated." To read more, see page 41 in the full issue.

DeNovX, a Chicago-based life sciences company, won the Best Pitch award at the American Chemical Society's National Entrepreneur Showcase East on April 9, 2014 in Waltham, MA. Nineteen entrepreneurs from across the US delivered 12 minute pitches on their chemistry-related businesses, and the diverse group included both first-time and serial entrepreneurs.  Business opportunities in the fields of nanotechnology, cleantech, semiconductors, diagnostic tests, medical devices, scientific instruments, and pharmaceuticals were presented.  The American Chemical Society is the world's largest scientific organization with 161,000 members and has as one of its missions to cultivate entrepreneurship to facilitate new job creation in the chemical [...]

Chicago, June 5, 2013 - Illinois Institute of Technology (IIT) and DeNovX, LLC, an Illinois-based life sciences company, are pleased to announce that DeNovX has licensed from IIT five issued patents providing improved processing methods for pharmaceutical R&D and production.  The technologies involve breakthrough methods of forming crystalline materials of relevance to pharmaceutical manufacturing and were developed from research performed in the Department of Chemical Engineering at IIT over a six year period, with financial support from both public and commercial sources.   "IIT has high confidence in the ability of DeNovX to successfully bring these technologies to the pharmaceutical markets,” said [...]